Scholar Rock Holding (SRRK) Other Accumulated Expenses (2017 - 2026)
Scholar Rock Holding's (SRRK) quarterly Other Accumulated Expenses came in at $775000.0 in Q1 2026, up 3.47% year-on-year from $749000.0 in Q1 2025, and down 45.35% quarter-over-quarter from $1.4 million in Q4 2025.
Scholar Rock Holding (SRRK) Other Accumulated Expenses (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Other Accumulated Expenses history runs 10 years deep, the most recent figure standing at $775000.0 for Q1 2026.
- On a quarterly basis, Other Accumulated Expenses rose 3.47% year-over-year to $775000.0 in Q1 2026; TTM through Mar 2026 was $775000.0, a 3.47% increase from a year earlier, with the FY2025 full-year figure at $1.4 million, up 61.32% from the prior year.
- Other Accumulated Expenses declined to $775000.0 in Q1 2026 per SRRK's latest filing, from $1.4 million in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $1.4 million in Q4 2025 and bottomed at $85000.0 in Q4 2023.
- The 5-year median for Other Accumulated Expenses is $831000.0 (2024), against an average of $783235.3.
- Across the five-year window, Other Accumulated Expenses tumbled 89.8% in 2023 and jumped 934.12% in 2024, its largest moves.
- Year by year, Other Accumulated Expenses stood at $833000.0 in 2022, then plunged by 89.8% to $85000.0 in 2023, then soared by 934.12% to $879000.0 in 2024, then jumped by 61.32% to $1.4 million in 2025, then slumped by 45.35% to $775000.0 in 2026.
- Per Business Quant, the three latest SRRK Other Accumulated Expenses figures stand at $775000.0 (Q1 2026), $1.4 million (Q4 2025), and $867000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,583.17 Bn | 67,582.89 Bn | - |
| 2 | Nanobiotix | 1,947.22 Bn | 1,947.15 Bn | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - |
| 4 | BeOne Medicines | 473.21 Bn | 468.42 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 123.29 Bn | 116.04 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.05 Bn | 61.29 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.09 Bn | 63.09 Bn | - |
| 8 | Argenx Se | 56.63 Bn | 51.45 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.79 Bn | 37.79 Bn | - |
| 10 | Scholar Rock Holding | 6.29 Bn | 6.29 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 775,000.00 |
| Dec 31, 2025 | 1.42 Mn |
| Sep 30, 2025 | 867,000.00 |
| Jun 30, 2025 | 1.13 Mn |
| Mar 31, 2025 | 749,000.00 |
| Dec 31, 2024 | 879,000.00 |
| Sep 30, 2024 | 831,000.00 |
| Jun 30, 2024 | 941,000.00 |
| Mar 31, 2024 | 914,000.00 |
| Dec 31, 2023 | 85,000.00 |
| Sep 30, 2023 | 825,000.00 |
| Jun 30, 2023 | 141,000.00 |
| Mar 31, 2023 | 769,000.00 |
| Dec 31, 2022 | 833,000.00 |
| Sep 30, 2022 | 731,000.00 |
| Jun 30, 2022 | 583,000.00 |
| Mar 31, 2022 | 846,000.00 |
| Dec 31, 2021 | 460,000.00 |
| Sep 30, 2021 | 381,000.00 |
| Jun 30, 2021 | 552,000.00 |